These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 25204470)

  • 1. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.
    Fardet L; Fève B
    Drugs; 2014 Oct; 74(15):1731-45. PubMed ID: 25204470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic and cardiovascular adverse events of systemic glucocorticoid therapy].
    Fardet L
    Rev Med Interne; 2013 May; 34(5):303-9. PubMed ID: 23313327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of systemic glucocorticoid side effects.
    Moghadam-Kia S; Werth VP
    Int J Dermatol; 2010 Mar; 49(3):239-48. PubMed ID: 20465658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Systemic glucocorticoid therapy: associated measures].
    Sailler L; Pugnet G; Arlet P
    Rev Med Interne; 2013 May; 34(5):279-83. PubMed ID: 23312495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic glucocorticoid therapy: risk factors for reported adverse events and beliefs about the drug. A cross-sectional online survey of 820 patients.
    Morin C; Fardet L
    Clin Rheumatol; 2015 Dec; 34(12):2119-26. PubMed ID: 25956956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoids and cardiovascular risk factors.
    Strohmayer EA; Krakoff LR
    Endocrinol Metab Clin North Am; 2011 Jun; 40(2):409-17, ix. PubMed ID: 21565675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications.
    Isidori AM; Graziadio C; Paragliola RM; Cozzolino A; Ambrogio AG; Colao A; Corsello SM; Pivonello R;
    J Hypertens; 2015 Jan; 33(1):44-60. PubMed ID: 25415766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Complications in Adrenal Insufficiency.
    Ueland GA; Husebye ES
    Front Horm Res; 2018; 49():104-113. PubMed ID: 29894991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glucocorticoid-induced osteoporosis: recent findings].
    Angeli A; Osella G; Reimondo G; Terzolo M
    Ann Ital Med Int; 2000; 15(1):47-55. PubMed ID: 10842891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could Exogenous Insulin Ameliorate the Metabolic Dysfunction Induced by Glucocorticoids and COVID-19?
    Whyte MB; Vas PRJ; Umpleby AM
    Front Endocrinol (Lausanne); 2021; 12():649405. PubMed ID: 34220705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoids and cardiovascular disease.
    Walker BR
    Eur J Endocrinol; 2007 Nov; 157(5):545-59. PubMed ID: 17984234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid excess and hypertension.
    Baid S; Nieman LK
    Curr Hypertens Rep; 2004 Dec; 6(6):493-9. PubMed ID: 15527696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission.
    Schernthaner-Reiter MH; Siess C; Gessl A; Scheuba C; Wolfsberger S; Riss P; Knosp E; Luger A; Vila G
    Endocrine; 2019 Apr; 64(1):157-168. PubMed ID: 30467627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study.
    Di Dalmazi G; Vicennati V; Rinaldi E; Morselli-Labate AM; Giampalma E; Mosconi C; Pagotto U; Pasquali R
    Eur J Endocrinol; 2012 Apr; 166(4):669-77. PubMed ID: 22267278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cushing's syndrome: update on signs, symptoms and biochemical screening.
    Nieman LK
    Eur J Endocrinol; 2015 Oct; 173(4):M33-8. PubMed ID: 26156970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid treatment and cardiovascular disease.
    Ng MK; Celermajer DS
    Heart; 2004 Aug; 90(8):829-30. PubMed ID: 15253942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term consequences of polycystic ovary syndrome].
    Grigoryan OR; Zhemaite NS; Volevodz NN; Andreeva EN; Melnichenko GA; Dedov II
    Ter Arkh; 2017; 89(10):75-79. PubMed ID: 29171475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.